IL6 and cardiac hypertrophy: Considering HDAC9's essential physiological functions and its involvement in tumor progression and cardiac hypertrophy,[20] specifically targeting HDAC7 without adversely impacting HDAC9's beneficial physiological functions presents a more favorable therapeutic approach for alleviating inflammation associated with excessive IL‐6 and TNF‐α production.